Japanese Journal of Clinical Oncology 32:449-454 (2002)
© 2002 Foundation for Promotion of Cancer Research
Low-dose Weekly Paclitaxel as Second-line Treatment for Advanced Non-small Cell Lung Cancer: a Phase II Study
Departments of 1 Medical Oncology and 2 Neurophysiology, Hospital Arnau de Vilanova, Valencia, Spain
Purpose: To assess the activity and toxicity of low-dose weekly paclitaxel in patients with non-resectable or metastatic non-small cell lung cancer (NSCLC) and who had disease recurrence or failure with previous chemotherapy.
Patients and methods: Forty patients with NSCLC previously treated with platinum-based chemotherapy received weekly paclitaxel 80 mg/m2 as a 1 h infusion. The median age was 63 years (range 42–77 years); 25 patients had Eastern Cooperative Oncology Group performance status (PS) 1 and 15 had PS 2. Thirty-one patients had stage IV disease and nine stage III (eight stage IIIB and one stage IIIA).
Results: A total of 364 weeks of treatment were administered (median 8 weeks, range 2–17 weeks). There were no episodes of grade 3 or 4 haematological toxicities. Severe non-haematological toxicity was uncommon: grade 1–2 asthenia in 50%; grade 1–2 motor neuropathy in 45% and grade 3 in 10%; grade 1–2 sensory neuropathy in 62% of patients. Alopecia was mild. The overall response rate was 37.5% (95% CI, 23.9–55): 2 CR, 13 PR, 15 SD, 8 PD, 2 NE. Median overall survival was 9.7 months (95% CI, 6.5–12.8). Median time to progression was 5.4 months (95% CI, 1.8–8.9).
Conclusion: A low-dose weekly paclitaxel regimen had good clinical efficacy with low toxicity in this group of patients with poor prognosis. This regimen increases the therapeutic options available for second-line therapy in NSCLC patients.
+ For reprints and all correspondence: Oscar Juan, Department of Medical Oncology, Hospital Arnau de Vilanova, C/ San Clemente 12, 46015 Valencia, Spain. E-mail juan_osc@gva.es
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Schuette, S. Nagel, T. Blankenburg, C. Lautenschlaeger, K. Hans, E.-W. Schmidt, I. Dittrich, H. Schweisfurth, L. F. von Weikersthal, A. Raghavachar, et al. Phase III Study of Second-Line Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel J. Clin. Oncol., November 20, 2005; 23(33): 8389 - 8395. [Abstract] [Full Text] [PDF]
|
|